Previous studies examining the effect of SGLT2 inhibitor use on exercise tolerance in nondiabetic patients with HF have shown that the prescription of SGLT2 inhibitors contributed to the improvement in exercise tolerance (peak VO2, 6 MWD) [21,22]. Here, SLC5A2 is linked to hydrops fetalis.